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http://www.molecular-cancer.com/content/13/1/49RESEARCH Open AccessReduced expression of AMPK-β1 during tumor
progression enhances the oncogenic capacity of
advanced ovarian cancer
Cuilan Li1,3, Vincent WS Liu1, Pui Man Chiu1, Kwok-Ming Yao2, Hextan YS Ngan1* and David W Chan1*Abstract
AMP-activated protein kinase (AMPK) is a key energy sensor that is involved in regulating cell metabolism. Our
previous study revealed that the subunits of the heterotimeric AMPK enzyme are diversely expressed during ovarian
cancer progression. However, the impact of the variable expression of these AMPK subunits in ovarian cancer
oncogenesis remains obscure. Here, we provide evidence to show that reduced expression of the AMPK-β1 subunit
during tumor progression is associated with the increased oncogenic capacity of advanced ovarian cancer cells.
Immunohistochemical analysis revealed that AMPK-β1 levels were reduced in advanced-stage (P = 0.008), high-grade
(P = 0.013) and metastatic ovarian cancers (P = 0.008). Intriguingly, down-regulation of AMPK-β1 was progressively reduced
from tumor stages 1 to 3 of ovarian cancer. Functionally, enforced expression of AMPK-β1 inhibited ovarian-cancer-cell
proliferation, anchorage-independent cell growth, cell migration and invasion. Conversely, depletion of AMPK-β1 by siRNA
enhanced the oncogenic capacities of ovarian cancer cells, suggesting that the loss of AMPK-β1 favors the aggressiveness
of ovarian cancer. Mechanistically, enforced expression of AMPK-β1 increased AMPK activity, which, in turn, induced
cell-cycle arrest via inhibition of AKT/ERK signaling activity as well as impaired cell migration/invasion through the
suppression of JNK signaling in ovarian cancer cells. Taken together, these findings suggest that the reduced expression
of AMPK-β1 confers lower AMPK activity, which enhances the oncogenic capacity of advanced-stage ovarian cancer.
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Ovarian cancer is one of the deadliest diseases that affects
females worldwide. The high mortality of this cancer is due
to its poor prognosis; therefore, most cases are diagnosed at
the advanced stage with metastatic functions [1,2]. In spite
of advances in treatment over the past decade, the cure rate
of ovarian cancer has improved modestly [2]. Therefore,
better targeted therapies and biomarkers for diagnosis or
prognosis are urgently needed. Recently, increasing evi-
dence has shown that cancer cells display an altered metab-
olism; therefore, targeting abnormal cancer metabolism is a
promising therapeutic approach for cancer surveillance
[3,4]. Hence, the study of key regulators of cellular metabol-
ism in cancer cells has attracted attention [5-9].* Correspondence: hysngan@hku.hk; dwchan@hku.hk
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unless otherwise stated.AMP-activated protein kinase (AMPK) is a well-known
cellular energy–balancing sensor [10-12] that regulates
cellular metabolism and protects living cells from environ-
mental stresses, such as hypoxia and nutrient deficiency,
which lead to elevations in the cellular AMP/ATP ratio.
Recent evidence suggests that AMPK has a dual role in
tumors. In metabolic stress microenvironements, such as
the nutrient or oxygen deprivation conditions in early
stage tumors where new blood vessels have not been
formed or during the transformation state of normal cells,
activated AMPK increases cell survival by regulating cellu-
lar NADPH levels to remove reactive oxygen species
(ROS) [13]. On the other hand, AMPK activation is in-
volved in inhibiting cell proliferation by suppressing
mTOR and upregulating p53 pathways [14,15]. In fact,
AMPK has been shown to possess a strong capacity to in-
hibit the cell growth of advanced-stage cancers [13,16,17].
Pharmacological activation of AMPK by AICAR or met-
formin commonly shows a strong inhibition of cell growthhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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such as chronic myelogenous leukemia (CML) and Ph +
acute lymphoblastic leukemia (ALL) [18,19] as well as
breast [20], cervical [16] and ovarian [17,21] cancers, which
indicates that AMPK activity may hinder or enhance cancer
oncogenesis. When and how tumor cells modulate AMPK
activity during tumor progression is currently unclear.
AMPK is a heterotrimer composed of a catalytic subunit
(α) and two regulatory subunits (β and γ), and all three sub-
units are essential for AMPK activity [22]. Multiple iso-
forms (encoded by distinct genes) of various AMPK
subunits, namely, α1, α2, β1, β2, γ1, γ2 and γ3, have been
reported. As mentioned, the functional aspects of AMPK in
metabolic diseases and human cancers have been exten-
sively studied and reviewed [23-25]. However, the expres-
sion status of various AMPK subunits and their functional
significance in human cancers have been sporadically
investigated.
We previously reported a comprehensive study of AMPK
subunits in ovarian cancer and showed that all subunits
are generally upregulated in ovarian cancer [26]. Intri-
guingly, the overexpressed AMPK-β1 that was found in
early stages of ovarian cancer were significantly reduced
in advanced stage ovarian cancer [26]. Given that post-
translation modifications of AMPK-β1 (i.e., myristoyla-
tion and phosphorylation) are essential for AMPK activity
[27], the expression status of AMPK-β1 may determine
the AMPK activity in ovarian cancer progression.
In this study, we further investigated the expression
and functional roles of the AMPK-β1 subunit in ovarian
cancer. We demonstrated a progressive reduction in the
expression of the AMPK-β1 subunit from early to late-stage
ovarian cancer, whereas enforced expression of AMPK-β1
could inhibit the cell growth and other aggressive capacities
of ovarian cancer cells through the AKT/ERK and JNK sig-
naling pathways. Overall, our findings underscore the im-
portance of AMPK-β1 in carcinogenesis through its ability
to modulate AMPK activity and other oncogenic pathways
during the progression of ovarian cancer.
Materials and methods
Ovarian cancer tissue array and cancer cell lines
Four ovarian cancer cell lines were used: A2780cp and
OV2008 were obtained from Prof. B.K. Tsang (Depart-
ment of Obstetrics and Gynecology, University of Ottawa),
and SKOV3 and OVCA433 were obtained from ATCC
(Rockville, MD, USA). Cell line authentication was per-
formed using an in-house STR DNA profiling analysis, and
the cell lines were cultured in minimum essential medium
(MEM) supplemented with 10% FBS (Gibco, Invitrogen
Life Technologies, Carlsbad, CA, USA) inside an incubator
containing 5% CO2 at 37°C. An ovarian cancer tissue array
(OVC1021) (Pantomics Inc., San Francisco, CA, USA),
which consists of five cases of normal/benign tumors and97 cases of ovarian cancers, was used for immunohisto-
chemical analysis.
Plasmids and DNA transfection
The pcDNA3.1–AMPK-β1–Flag-tagged plasmid (a gift
from Prof. Yi Sun, University of Michigan, USA) was used
to overexpress AMPK-β1 in ovarian cancer cells, and Li-
pofectamine™ 2000 Transfection Reagent (Invitrogen) was
used for transfection experiments. Stable AMPK-β1-over
expressing clones were established from AMPK-β1 trans-
fected cells using G418 selection. The shRNA plasmid
shRNA-AMPK-β1 (shβ1) for targeting against AMPK-β1
was purchased from OriGene Technologies, Inc. (Rockville,
MD, USA). Stable, AMPK-β1 knockdown clones were
established by puromycin selection of shβ1-transfected
cells, and all of the clones were verified by western blot
analysis. The pEGFP- AMPK-β1 plasmid was used for im-
munofluorescence analysis and was constructed by sub-
cloning AMPK-β1 from the pcDNA3.1–AMPK-β1–Flag
tagged plasmid into pEGFP-C1 (Clontech Laboratories,
Inc., Mountain View, CA, USA ).
Western blot, immunofluorescence and
immunohistochemical analyses
Cells were lysed in lysis buffer containing a protease inhibi-
tor and phenyl-methyl-sulfonyl-fluoride (Cell Signaling
Technology, Beverly, MA, USA). Equal amounts of each
sample were fractionated by SDS-PAGE and electroblotted
onto an Immobilon-P Membrane (Millipore, Billerica,
MA, USA). The membrane was blocked with 5% non-
fat dry milk in a TBS with Tween (TBST) solution at room
temperature for 1 h, followed by overnight incubation with
various primary antibodies. Antibodies against AMPK-β1,
AMPK-α, phospho-AMPK-α (Thr172), P70S6K, phospho-
P70S6K (Thr389), AKT, phospho-AKT (Ser473), mTOR,
and phospho-mTOR (Ser2448) were purchased from Cell
Signaling, whereas antibodies against JNK, phospho-JNK
(Thr183/Tyr185), ERK and phospho-ERK (Thr202/Tyr204)
were purchased from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA, USA). The blots were then incubated with goat
anti-rabbit or anti-mouse secondary antibodies that were
conjugated to horseradish peroxidase and visualized via
an enhanced chemiluminescence system (Amersham
Pharmacia Biotech, Cleveland, OH, USA). β-Actin (Sigma
Chemical Co. St Louis, MO, USA) was used as the loading
control.
For immunofluorescence analysis, SKOV3 cells were
cultured on cover slips and transiently transfected with
AMPK-β1-expressing plasmid. The preparation and exam-
ination of pEGFP-AMPK-β1-transfected cells were per-
formed as previously described [28].
Immunohistochemical (IHC) staining for AMPK-β1
was performed on an ovarian cancer tissue array (OVC
1021), and an antibody against AMPK-β1 (Cell Signaling
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PK-β1. Procedures and the scoring of results were per-
formed as previously described [29,30], and the examin-
ation of immunohistochemical staining was performed by
two independent observers.
Confocal microscopy
The cellular localization of AMPK-β1 was examined in
A2780CP and SKOV3 cells after the transient expression
of the pCMV6–AMPK-β1–GFP-tagged plasmid (OriGene
Technologies). The analytical procedure was reported pre-
viously [29], and fluorescence signals were captured using
confocal microscopy.
Cell proliferation assay
The cell proliferation assay was performed using a cell
proliferation kit (Invitrogen), and data were obtained
from three separate experiments that were performed in
triplicate.
Clonogenic assay
Approximately 800 cells were plated in triplicate in 6-well
plates to form colonies for up to 2–4 weeks, and the
medium was replaced every 3–7 days. The colonies were
then stained with crystal violet and counted.
Anchorage-independent growth assay
A soft agar colony formation assay was used to determine
the capacity of ovarian cancer cells to undergo anchorage-
independent cell growth upon different treatments. Sterile
2% (bottom) and 0.6% agarose gel (top) stocks in 2× MEM
containing 20% FBS were prepared, and single-cell suspen-
sions were prepared by suspending 1000 cells in 2 ml of
full medium containing 0.3% agar. The cell suspensions
were plated on top of a solidified bottom layer (~2 ml) with
1% agar in the full medium, and the plates were incubated
at 37°C in a humidified incubator for 14–21 days. The col-
onies were then counted using a dissecting microscope.
Flow cytometry
The DNA content, cell cycle distribution and percentage
of apoptotic cells of each sample were assessed by flow
cytometry. Cells were cultured in 6-well plates, and float-
ing and attached cells were harvested by trypsinization,
centrifuged and resuspended in PBS. The cells were then
fixed overnight with 1 ml of 70% ethanol at 4°C followed
by centrifugation at 4,000 × g at 4°C for 5 min and one
wash with ice-cold PBS. RNase A was heated at 95°C for
10 minutes before use, and the cell pellets were resus-
pended in 500 μl of PBS containing 5 μl of RNase A
(10 mg/ml stock) and then incubated at 37°C for 30 min.
Afterwards, 125 μl of propidium iodide (250 μg/ml) was
added to each sample and was kept at 4°C in dark before
flow cytometry.Wound healing, cell migration, and invasion assays
The wound healing assay was performed as follows. Equal
numbers of cells were cultured in full medium in a 6-well
plate until 90% confluency. Cells were then pretreated
with 10 μg/ml of mitomycin C for 2 h, and three parallel
“wounds” were created in each plate with a sterile 200 μl
pipette tip. The plate was then washed with PBS, and
the width of the wounds was photographed at differ-
ent time points (0, 12, 24 and 36 h). The relative vel-
ocity of cell migration was calculated as the change in
width/time.
Quantification of cell migration and invasion was per-
formed using QCM™ 24-Well Colorimetric Cell Migration
and Cell Invasion Assay Kits (Chemicon International,
Inc., Temecula, CA, USA). Briefly, cells were resuspended
in serum-free culture medium (5.0 × 104 cells for the cell
migration assay and 2.0 × 105 cells for the invasion assay)
and then seeded on the upper chamber. The full medium
was then placed in the lower chamber as a chemo-
attractant, and the cells were allowed to pass through the
pores to the lower surface of the membrane (18 h for cell
migration and 28 h for the cell invasion assay). The cells
were then stained with the staining buffer and photo-
graphed in three different microscopic fields.
Statistical analysis
The SPSS 14.0 software was used for statistical analysis
(SPSS, Chicago, IL, USA). Fisher’s exact test (for paramet-
ric data) and the Mann–Whitney test (for non-parametric
data) were used to compare the values between sub-
groups, and data were expressed as the mean ± SD. The
Student’s t-test was used to compare the values between
subgroups, and P < 0.05 was considered to be a statistically
significant difference between groups of data.
Results
Reduced expression of AMPK-β1 during ovarian
cancer progression
AMPK-β1 expression in clinical samples was analyzed
using immunofluorescence and IHC analyses. We first ex-
amined the subcellular localization of AMPK-β1 in ovarian
cancer cells. Using an immunofluorescence analysis, we
observed an accumulation of GFP/AMPK-β1 at the plasma
membrane and as punctate structures throughout the
cytoplasm of SKOV3 cells (Additional file 1: Figure S1).
However, our previous qPCR analysis showed that the
expression of AMPK-β1 was significantly reduced in
late-stage compared to early stage ovarian cancer [31].
Similarly, our current analysis using IHC also showed that
the AMPK-β1 level was reduced in early to advanced-stage
ovarian cancers. The reduced AMPK-β1 level was signifi-
cantly associated with late-stage (P = 0.008), high-grade
(P = 0.013) and metastatic ovarian cancers (P = 0.008)
(Table 1). More importantly, we observed that the
Table 1 Immunohistochemical analysis of AMPK-β1 on an
ovarian cancer tissue array (OVC1021, Pantomics, Inc.)
AMPKβ1 expression [fold change]
Characteristics Total ≤ 3-fold >3-fold P
All cases 97 57 (58.8) 40 (41.2)
Stage
Early (1 + 2) 73 37 (50.7) 36 (49.3)
Late (3) 24 20 (83.3) 4 (16.7) 0.008*
Grade
Low 50 23 (46.0) 27 (54.0)
High 46 33 (71.7) 13 (28.3) 0.013*
Metastasis
No 73 37 (50.7) 36 (49.3)
Yes 24 20 (83.3) 4 (16.7) 0.008*
Clinicopathological analysis showed that down-regulated AMPK-β1 (≤3-fold)
was associated with late stage (P = 0.008) and high-grade (P = 0.013) cancer
and the presence of metastasis (P = 0.008). P, p-value. *, statistical significance.
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duction pattern that accompanied the tumor-stage pro-
gression (from tumor stage 1 to stage 3) of ovarian
cancers (Figure 1A and B). This expression pattern was
consistent with the AMPK activity (examined by IHC
using anti- phospho-AMPKα (pAMPKα) on the same
tissue array) with the tumor stage (data not shown), in-
dicating that a progressive loss of AMPK-β1 expressionFigure 1 Expression of AMPK-β1 in ovarian cancer samples. (A) Immu
tissue array (OVC1021, Pantomics). Representative images showing the AMPK-β
highest level of AMPK-β1, while tumor stage 3 has the lowest level of AMPK-β1
from stage 1 to stage 3 ovarian cancers.occurs during the development and progression of ovar-
ian cancer.
Loss of AMPK-β1 enhances ovarian cancer cell growth
and anchorage-independent growth ability
Because AMPK-β1 was obviously reduced in advanced-
stage ovarian cancer, we investigated the effect of AM
PK-β1 on ovarian cancer cell growth and anchorage-
independent growth. Stable clones overexpressing AMPK-
β1 in two ovarian cancer cell lines (A2780cp and SKOV3)
with relatively lower AMPK-β1 level or depleted of AM
PK-β1 by shRNAi-mediated gene silencing in another two
ovarian cancer cell lines (OVCA433 and OV2008) with
relatively higher AMPK-β1 expression were generated
(Additional file 2: Figure S2). The XTT cell proliferation
assay demonstrated that enhanced expression of AMPK-β1
significantly inhibited ovarian cancer cell growth by 45 to
50% in A2780cp (C4, C5 and C11) (P < 0.002) and SKOV3
stable clones (C1, C2 and C3) (P < 0.001) compared with
the parental lines and vector controls (Figure 2A). Further-
more, transient upregulation of AMPK-β1 elevated pAM
PKα and mitigated cell proliferation in ovarian cancer cells
in a dose-dependent manner (Additional file 3: Figure S3).
Additionally, we demonstrated that enforced expression of
AMPK-β1 exhibited 60 to 70% less foci in A2780cp and
SKOV3 stable clones (P < 0.001) by the focus formation
assay (Figure 2B), and we demonstrated that the AMPK-
β1 overexpressed clones of A2780cp (C4, C5 and C11)nohistochemical analysis of AMPK-β1 expression using an ovarian cancer
1 expression in serous subtype ovarian cancer. Tumor stage 1 has the
(10x). (B) A graph showing the stepwise decrease of AMPK-β1 expression
Figure 2 (See legend on next page.)
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Figure 2 Overexpression of AMPK-β1 inhibits cell proliferation and anchorage-independent growth ability. (A) XTT cell proliferation assay
showing that enforced expression of AMPK-β1 in A2780cp (C4, C5 and C11) (P < 0.002) and SKOV3 (C1, C2 and C3) (P < 0.001) clones displaying a
45 to 50% decrease in the cell growth rate compared with the empty vector (V1) and the parental (P) cell control. (B) Focus formation assay
showing that the size and number of foci was reduced 2.5- to 3-fold in AMPK-β1 stable clones of A2780cp (C4 and C5) (P < 0.001) cells and 3- to
4-fold in AMPK-β1 stable clones of SKOV3 (C1 and C3) (P < 0.001) cells compared with the vector controls. (C) Soft agar assay revealing that the
AMPK-β1 stable clones of A2780cp (C4, C5 and C11) (P < 0.04) and SKOV3 (C1, C2 and C3) (P < 0.05) cells had a 2.5- to 3-fold reduction in the size
and number of colonies compared with the control. P: parental. V, V1 or V2: empty vector controls.
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showed a ~70% to 75% reduction in the number and size
of colonies compared with the vector controls by the focus
formation assay (Figure 2C). Conversely, by depleting en-
dogenous AMPK-β1 in OV2008 (P < 0.002) and OVCA
433 (P < 0.001) cells, which highly express AMPK-β1,
using the sh-β1 shRNA, we demonstrated that cell prolif-
eration increased 20-25% in all stable clones that overex-
pressed the sh-β1 shRNA (Figure 3A). Similarly, the stable
AMPK-β1 knockdown clones exhibited a 2-3-fold increase
in cell growth based on the focus formation assay (P <
0.001) (Figure 3B) and a 4-5-fold increase in colony for-
mation using the anchorage-independent growth ability
assay (P < 0.03) (Figure 3C).
Given that overexpression of AMPK-β1 could inhibit
ovarian cancer cell growth, we investigated how AMPK-
β1 affected the cell-cycle kinetics of ovarian cancer cells.
We then demonstrated that overexpression of AMPK-β1
induced G1 phase arrest in A2780cp (C4) and SKOV3
(C3) stables clones (P = 0.0001) compared to the controls
by a cell-cycle analysis using flow cytometry (Additional
file 4: Figure S4A and B). On the other hand, stable knock-
down of endogenous AMPK-β1 enhanced the G1 phase in
OV2008 (shβ1-C5) (P = 0.002) and OVCA433 (shβ1-C1)
cells (P = 0.001) (Additional file 4: Figure S4C and D).
In sum, these findings suggest that AMPK-β1 plays a sup-
pressive role in the cell growth and anchorage-independent
growth capacity of ovarian cancer cells by inducing G1-
phase arrest.Loss of AMPK-β1 promotes ovarian cancer cell migration
and invasion
We also studied the functional role of AMPK-β1 in ovar-
ian cancer cell migration and invasion. Using transwell
migration and invasion assays, enhanced AMPK-β1 ex-
pression was found to significantly attenuate the cell mi-
gration (P < 0.005) and invasive (P < 0.001) capacities of
SKOV3 stable clones (CC1 and C3) (Figure 4A and B).
In contrast, stable depletion of endogenous AMPK-β1 in
AMPK-β1-expressing OVCA433 cells (C1 and C12) using
the sh-β1 shRNA enhanced cell migration (P < 0.001) and
invasion (P < 0.0001) (Figure 4C and D). These results indi-
cate that down-regulation of AMPK-β1 enhances the ag-
gressiveness of ovarian cancer and explains why its level isprogressively decreased in advanced stage and high-grade
ovarian cancers.
AMPK-β1 modulates AKT /mTOR and JNK pathways
Because AMPK-β1 is a subunit of the AMPK complex, we
further examined its functional role in AMPK activity.
Western blot analysis demonstrated that AMPK activity,
reflected by the levels of phospho-AMPKα (pAMPKα) and
phospho-ACC (pACC), was significantly elevated in all
stable, AMPK-β1-overexpressing, A2780cp (C4, C5 and
C11) and SKOV3 (C1, C2 and C3) clones compared with
the vector controls (Figure 5A, left panel). Additionally, we
found that these stable AMPK-β1 clones exhibited a large
reduction in the expression of pAKT (Ser473), pmTOR
(Ser2448) and pP70S6K (Figure 5A, right panel). In con-
trast, depletion of AMPK-β1 in the OV2008 (C2, C5 and
C32) and OVCA433 (C1, C12 and C23) clones decreased
AMPK activity but increased the levels of pAKT (Ser473),
pmTOR (Ser2448) and pP70S6K (Figure 5B). Interestingly,
we observed that the stable, AMPK-β1-overexpressing
SKOV3 clones (C1 and C2) exhibited a stronger induction
of pAMPKα upon treatment with metformin (Figure 5C),
indicating that increased AMPK-β1 enhances AMPK ac-
tivity, which, in turn, reduces AKT and mTOR signaling
activities. Because the AKT and mTOR signaling pathways
have been widely reported to be associated with cancer-
cell growth, an increase in AMPK accompanied with a re-
duction in AKT and mTOR would no doubt inhibit cell
growth and the anchorage-independent growth capacities
of ovarian cancer cells.
Furthermore, by using the transient transfection of
AMPK-β1 in A2780cp cells, we found that the activities of
AKT, ERK and JNK (pERK and pJNK (Thr183/Tyr185))
were inhibited (Additional file 3: Figure S3 & Additional
file 5: Figure S5). However, depletion of AMPK-β1 in
OV2008 and OVCA433 cells showed opposing results
in that JNK and ERK activities (pERK and pJNK (Thr183/
Tyr185)) were elevated (Figure 5D). Because ERK and
JNK signaling are involved in cell migration/invasion, the
inhibition of these pathways by AMPK-β1 overexpression
supports the findings that enhanced expression of AMPK-
β1 suppressed cell migration and invasion in ovarian
cancer cells.
Taken together, our results suggest that re-expression
of AMPK-β1 inhibits cell proliferation and cell migration/
Figure 3 Depletion of AMPK-β1 promotes cell proliferation and anchorage-independent growth ability. (A) XTT cell proliferation assay
demonstrating that OV2008 (C2, C5 and C32) (P < 0.002) and OVCA433 (C1, C12 and C23) (P < 0.001) clones exhibited a 20-25% reduction in cell
proliferation. (B) Focus formation assay showing that all AMPK-β1 stable knockdown clones in A2780cp (C2 and C5) (P < 0.001) and OVCA433
(C1 and C12) (P < 0.001) cells expressed a 2 to 3-fold increase in the number of foci. (C) Soft agar assay showing that knockdown of AMPK-β1 in
OV2008 (C2 and C5) (P < 0.03) and OVCA433 (C1 and C12) (P < 0.03) cells had a 4-5-fold increase in the number and size of colonies. P: parental.
V, V1 or V2: empty vector controls.
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Figure 4 AMPK-β1 regulates cell migration and invasion of ovarian cancer cells. Enhanced expression of AMPK-β1 in SKOV3 (C1 and C3)
cells resulted in a reduced cell migratory rate (3 to 3.5-fold) using (A) the transwell cell migration assay (P < 0.005) and a 3.5-fold decrease in the
cell invasive rate using (B) the transwell cell invasion assay (P < 0.001). Conversely, depletion of endogenous AMPK-β1 in OVCA433 (C1 and C12)
by shRNA knockdown enhanced the cell migration rate by 8- to 12-fold using (C) the transwell cell migration assay (P < 0.001) and resulted in a
7- to 12-fold increase in the cell invasive rate using (D) the transwell cell invasion assay (P < 0.0001). V1 and V2 are the empty vector controls for
OVCA433 and SKOV3, respectively.
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AMPK activity but reducing AKT/ERK, JNK and mTOR
signaling activities.
Discussion
AMPK is a well-known energy sensor in mammalian cells
[32]. Emerging evidence has demonstrated that AMPK ex-
erts promoting and suppressing effects on tumor onco-
genesis depending on the cancer cell type and the timing
of tumor development. Recent studies show that AMPK
enhances cell survival during metabolic stress in earlystage tumors or when tumor cells detach from their extra-
cellular matrix [13,33]. However, mounting evidence also
suggests that low AMPK activity usually favors high cell
proliferation in numerous, advanced-stage human cancers
[34-36]. Yet, the underlying molecular mechanism for
modulating AMPK activity-mediated cell proliferation in
cancers remains unclear. In this study, we report that the
AMPK-β1 subunit of the AMPK complex shows a pro-
gressive reduction in expression level from early to ad-
vanced tumor stages of ovarian cancer. We found that the
reduced AMPK-β1 is consistent with the lower AMPK
Figure 5 AMPK-β1 positively regulates AMPK but negatively modulates AKT/mTOR, ERK and JNK activities. (A) AMPK-β1 overexpression
in A2780cp (C4, C5 and C11) and SKOV3 (C1, C2 and C3) cells activated AMPK (increased pAMPKα and pACC (left panel)) but reduced AKT (pAKT)
and mTOR (pmTOR and pP70S6K) activities (right panel). (B) Knockdown of AMPK-β1 in OV2008 (C2, C5 and C32) and OVCA433 (C1, C12 and
C23) cells by shRNA suppressed AMPK activity (decrease of pAMPKα and pACC (left panel)) but elevated AKT (pAKT) and mTOR (pmTOR and
pP70S6K) activities (right panel). (C) AMPK-β1 overexpression sensitizes ovarian cancer cells to an AMPK activator, metformin, during AMPK activation.
SKOV3 cells were treated with the AMPK activator, metformin, at 0-, 2-, and 10-mM concentrations. Stable clones overexpressing AMPK-β1 (C1, C2, C4,
and C5) were more sensitive to metformin (2 mM) in the presence of elevated pAMPKα compared with the two empty vector controls (V2 and V3).
(D) Depletion of AMPK-β1 activates the ERK and JNK pathways, and knockdown of AMPK-β1 in OV2008 (C2, C5 and C32) and OVCA433 (C1, C12 and
C23) cells led to an increase in JNK (pJNK) and ERK (pERK) signaling activities.
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metastatic ovarian cancers. Using gain- and loss-of-function
strategies, we demonstrated that AMPK-β1 profoundlyimpairs cell growth, migration and invasion capacities via
activating AMPK but attenuating AKT, ERK and JNK activ-
ities in advanced ovarian cancer cells. To our knowledge,
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pression, function and mechanism of action in human
cancer cells.
Recent studies have suggested that AMPK acts as a
metabolic tumor suppressor due to its roles in governing
the activities of mTOR, p53 and other regulatory mole-
cules as well as fatty acid synthesis [37-39]. Hence, tumor
cells must reduce the activity of AMPK to maintain their
high proliferative capacity in oncogenesis. Loss of LKB1 is
a well-known mechanism in suppressing AMPK activity
and is commonly found in lung cancer, melanoma, gastro-
intestinal carcinoma and dysplastic hamartoma in Peutz-
Jeghers syndrome [40-42]. However, most human cancers
with an intact LKB1 function still maintain low AMPK ac-
tivity when exerting their tumorigenic properties [43-45],
indicating that multiple mechanisms exist that depress
AMPK activity in such cancer cells. AMPK is a heterotri-
meric complex consisting of a catalytic alpha-subunit and
regulatory beta- and gamma-subunits. We previously re-
ported that the AMPK subunits are differentially expressed
and that different subunits have different clinical implica-
tions in the development of ovarian cancer [46]. Of these
subunits, we found that the mRNA level of AMPK-β1 was
dominantly expressed and tightly correlated with AMPK
activity when compared with AMPK-β2 during the pro-
gression of ovarian cancer [47] and other human cancers
[48]. Consistent with our previous findings, the IHC data
in this study further demonstrates that AMPK-β1 expres-
sion shows a stepwise reduction from early to late-stage
ovarian cancer. In addition, reduced AMPK-β1 expression
shows a significant association with late-stage, high-grade
and metastatic ovarian cancers, suggesting that reduced
AMPK-β1 expression decreases AMPK activity and en-
hances the aggressiveness of advanced ovarian cancer. Al-
though the underlying molecular mechanisms leading to
the downregulation of AMPK-β1 during ovarian cancer
progression remain unknown, the recent finding of the un-
derexpression of AMPK-α2 in liver cancer cells [49] indi-
cates that DNA methylation and histone deacetylation
may be involved in silencing the expressions of AMPK
subunits in ovarian cancer cells.
Our results indicate that the inhibitory effect of AMPK-
β1 on cell growth is mediated through an increase in
AMPK activation and a simultaneous decrease in AKT
pathway activity. In the AMPK heterotrimeric complex, the
AMPK-β subunit acts as a scaffold to support the binding
of the catalytic α and regulatory γ subunits [50,51]. We
postulated that AMPK-β1 upregulation most likely leads
to an increase in the number of AMPK heterotrimeric
complexes, which, in turn, facilitates induced activation
of AMPK by either microenvironemental stresses or
pharmaceutical activators. In contrast, lower AMPK-β1
expression may reduce the number of AMPK heterotri-
meric complexes, which leads to lower AMPK activityin advanced ovarian cancers. A previous study has dem-
onstrated that knockouts of AMPK-β1 and -β2 led to
reduced AMPK activity in most tissues and significant
reductions in bone mass in mice [52]. Additionally, the
post-translational modification of AMPK-β1, that is,
myristoylation and phosphorylation, could affect AMPK
activity [53]. Based on these findings, we believe that re-
duced expression of AMPK-β1 diminishes the amount
of AMPK heterotrimeric complexes and their activity in
aggressive, advanced ovarian cancer cells.
Our findings on the negative regulation of the AKT
pathway by AMPK-β1 is in line with those reported by
Feng et al. [54]. AMPK-β1 has been found to be a stress-
responsive gene that can be induced in a p53-dependent or
p53-independent manner [54,55]; therefore, induction of
AMPK-β1 expression could negatively regulate the IGF-1–
AKT–mTOR pathways [56]. The ability to simultaneously
upregulate AMPK activity and down-regulate AKT signal-
ing leads to cell growth inhibition. Moreover, AMPK-β1
overexpression could inhibit ovarian cancer cell migration
and invasion, and this effect is most likely mediated
through the down-regulation of the JNK pathway. We have
previously demonstrated that down-regulation of the JNK
pathway using a JNK inhibitor (SP600125) significantly
inhibited cell motility [57]. Similarly, inhibition of the AKT
and ERK pathways using their respective inhibitors, wort-
mannin and U0126, could reduce cell proliferation rates
[57], which indicates the importance of AMPK-β1 ex-
pression in controlling cell proliferation, migration, and
invasion. Indeed, AMPK-β1 expression correlates well
with clinicopathologic data, which show that early stage
tumors have high levels of AMPK-β1, whereas advanced
stage, high-grade or metastatic ovarian cancers have
lower AMPK-β1 levels.
In conclusion, our findings suggest that the expression
level of AMPK-β1 is able to determine the amount of
AMPK heterotrimeric complexes and, hence, the activity
level of AMPK in advanced ovarian cancer cells. Downreg-
ulation of AMPK-β1 seems to be another mechanism that
leads to lower AMPK activity in advanced ovarian cancer
cells. Based on the data showing that enforced expression
of AMPK-β1 elevates AMPK activity but decreases AKT,
ERK and JNK activities as well as abrogates its oncogenic
capacities in cell growth, migration, invasion and sensitizing
chemoresistant ovarian cancer cells to cisplatin-induced cell
apoptosis, AMPK-β1 may be a potential therapeutic target
in advanced ovarian cancer treatment.Additional files
Additional file 1: Figure S1. Immunofluorescence analysis of AMPK-β1
localization in ovarian cancer cells. The GFP-AMPK-β1 fusion protein could
be visualized mainly at the membrane and as punctate structures
throughout the cytoplasm of SKOV3 cells (indicated by the arrows).
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http://www.molecular-cancer.com/content/13/1/49Additional file 2: Figure S2. Generation of AMPK-β1 overexpression
and knockdown stable clones in ovarian cancer cells. (A) The pcDNA3.
1–AMPK-β1–Flag tagged plasmid was transfected into A2780cp and
SKOV3 cells. After drug selection, the positive Flag/AMPK-β1 expressing
clones were verified by western blotting using anti-Flag. (B) The shRNA
plasmid (shRNA-AMPK-β1, shβ1) was transfected into OVCA433 and
OV2008 cells. After drug selection, the positive AMPK-β1 knockdown
clones were verified by western blotting using anti-AMPK-β1. V1, V2 and
V3 were empty vector control clones. P, the parental ovarian cancer cells.
SC, scrambled control.
Additional file 3: Figure S3. Transient transfection of AMPK-β1 not
only upregulates AMPK activity but also reduces cell proliferation. (A)
Western blot analysis showed that transient transfection of Flag/AMPK-β1
expressing plasmid into A2780cp and SKOV3 cells showed an increase in
AMPK activity (pAMPKα) but a reduced AKT activity (pAKT) in a dose
dependent manner of AMPK-β1 of both cell lines. (B) XTT cell proliferation
assay showed that transient transfection of Flag/AMPK-β1 expressing plas-
mid into SKOV3 cells showed a reduced cell proliferation rate dose depend-
ently. The relative cell proliferation was calculated by comparing the cell
proliferation index on Day 5 to Day 1. *P < 0.05.
Additional file 4: Figure S4. Cell cycle analysis showed AMPK-β1
induced G1-phase arrested in ovarian cancer cells. The overexpressed
AMPK-β1 in (A) A2780cp (C4) (P = 0.0001), and (B) SKOV3 (C3) (P = 0.0001),
induced 30-110% increase in G1 phase but 0.8- to 1.5-fold reduction in
G2- and S-phases, when compared with their vector controls (V1 and V2). In
contrast, stable knockdown of AMPK-β1 in (C) OV2008 (shβ1C5) (P = 0.002),
and (D) OVCA433 (shβ1C1) (P = 0.001) caused 35 to 40% decrease in G1
phase but 0.5- to 2.0-fold reduction in G2- and S-phases, when compared
with their vector controls (V1 and V2).
Additional file 5: Figure S5. AMPK-β1 inhibits ERK and JNK signaling
activities in ovarian cancer cells. Western blot analysis revealed that
transient transfection of pcDNA3.1–AMPK-β1–Flag tagged plasmid (β1)
into A2780cp with various doses (0.5, 1, 2 and 3 μg) inhibited the
expressions of pERK and pJNK dose dependently.
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